Immix Biopharma, Inc. (IMMX) Stock Price & Analysis
Immix Biopharma, Inc. (IMMX) rose 1.78% to USD 8.01 as of June 10, 2026 at 07:39 UTC, according to Nexqual real-time market data.
IMMX last closed at USD 7.87; the session ranged USD 7.8–8.23 on volume of 1,329,694 shares. Market capitalization is $570.23M, with a 52-week range of USD 1.94–11.61 (NCM). Source: Nexqual, June 10, 2026 at 07:39 UTC.
Key Statistics (as of June 10, 2026 at 07:39 UTC)
| Price | USD 8.01 |
|---|---|
| Change | ▲ 1.78% (up) |
| Previous Close | USD 7.87 |
| Open | USD 8.01 |
| Day Range | USD 7.8 – 8.23 |
| 52-Week Range | USD 1.94 – 11.61 |
| Volume | 1,329,694 shares |
| Market Cap | $570.23M |
| Exchange | NCM |
Technical Analysis (IMMX)
Nexqual's technical model rates IMMX "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 34.39 (neutral) |
| vs SMA50 | Below (USD 9.27) |
| MACD | -0.36 (negative) |
Analyst Ratings (IMMX)
Wall Street analysts rate IMMX "Strong Buy" based on 5 analysts, with a mean price target of USD 18.46 (range USD 14.5–22.78), per Nexqual as of June 10, 2026 at 07:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 18.46 |
| High Target | USD 22.78 |
| Low Target | USD 14.5 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (IMMX)
| EPS Estimate | USD -0.18 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.18 vs est -0.21 ▲ beat |
| 2025-12-31 | USD -0.28 vs est -0.16 ▼ miss |
| 2025-09-30 | USD -0.24 vs est -0.19 ▼ miss |
| 2025-06-30 | USD -0.22 vs est -0.16 ▼ miss |
Source: Nexqual, June 10, 2026 at 07:39 UTC.
Financials & Fundamentals (IMMX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -74.46% |
| Debt / Equity | 1.23 |
| Current Ratio | 8.76 |
| Total Cash | $90.58M |
| Total Debt | $1.04M |
| Free Cash Flow | $-20.03M |
Source: Nexqual, June 10, 2026 at 07:39 UTC.
Financial Health Score (IMMX)
Nexqual rates Immix Biopharma, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:39 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $91M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$32M |
| Efficiency | Critical — ROE -74%, ROA -39.0% |
Ownership (IMMX)
| Insider Ownership | +17.56% |
|---|---|
| Institutional Ownership | +45.15% |
| Shares Outstanding | 71.19M |
| Float | 40.34M |
| Short % of Float | +6.85% |
Source: Nexqual, June 10, 2026 at 07:39 UTC.
Leadership (IMMX)
Immix Biopharma, Inc. is led by Ilya Rachman M.B.A. (age 52), Co-Founder, CEO, Chief Scientific Officer & Chairman, per Nexqual as of June 10, 2026 at 07:39 UTC.
| Co-Founder, CEO, Chief Scientific Officer & Chairman | Ilya Rachman M.B.A. (age 52) |
|---|---|
| President, CFO & Director | Gabriel Morris B.A. (age 38) |
Major Backers & Investors (IMMX)
Notable institutional backers of Immix Biopharma, Inc. include Janus Henderson Group PLC, Saturn V Capital Management LP, Eventide Asset Management LLC, according to Nexqual as of June 10, 2026 at 07:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 8.83% |
| Saturn V Capital Management LP | 6.79% |
| Eventide Asset Management LLC | 4.68% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 4.68% |
| Millennium Management | 3.22% |
| Marshall Wace LLP | 3.02% |
| Logos Global Management LP | 2.25% |
| Bleichroeder LP | 1.84% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.49% |
Source: Nexqual, June 10, 2026 at 07:39 UTC.
From Immix Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Any resulting patents in this family are expected to expire in 2043 (not including any patent term adjustment and patent term extension in the United States and equivalents in foreign countries).     We also have global exclusive rights to PCT Application No.
- We believe that we have substantial know-how and trade secrets relating to our technology and product candidates.     As of March 2026, we have global exclusive rights to PCT Application No.
- The global amyloidosis treatment market size was estimated at $5.80 billion in 2024 and is projected to reach $11.13 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033, according to Grand View Research.   As of March 2026, there are no FDA approved drugs for relapsed/refractory AL Amyloidosis.   Figure 2: NXC-201 Addresses Sizable U.S.
- CAR-T cell therapy is a type of immunotherapy that uses the patient's own immune cells, modified with our proprietary technology, to create NXC-201, which is then introduced into the patient's body.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BFRI | Biofrontera Inc. | USD 0.88 | ▼ 5.88% |
| KTTA | Pasithea Therapeutics Corp. | USD 0.58 | ▼ 0.85% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| NRSN | NeuroSense Therapeutics Ltd. | USD 0.76 | ▲ 1.33% |
| PTPI | Petros Pharmaceuticals, Inc. | USD 0.01 | ▲ 8.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:39 UTC. This page is informational and not investment advice.